oral, brain-penetrant O-GlcNAcase (OGA) inh.

structurally distinct in vivo tool

from virtual screen of 100k cmpd, testing 2681

J. Med. Chem., Jan. 6, 2021

Takeda Pharmaceutical, Fujisawa, JP

The Takeda O-GlcNAcase (OGA) inhibitor, “compound 5i,” binds to the same site as prior sugar-based OGA inhibitors, but has surprisingly different chemical properties and a unique binding mode. The…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks